

## Product datasheet for **TL311836V**

### Cytokeratin 16 (KRT16) Human shRNA Lentiviral Particle (Locus ID 3868)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Cytokeratin 16 (KRT16) Human shRNA Lentiviral Particle (Locus ID 3868)
Locus ID:	3868
Synonyms:	CK16; FNEPPK; K1CP; K16; KRT16A; NEPPK; PC1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	KRT16 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_005557</a> , <a href="#">NM_005557.1</a> , <a href="#">NM_005557.2</a> , <a href="#">NM_005557.3</a> , <a href="#">BC039169</a> , <a href="#">BC039169.1</a> , <a href="#">BM786499</a> , <a href="#">NM_005557.4</a>
UniProt ID:	<a href="#">P08779</a>
Summary:	The protein encoded by this gene is a member of the keratin gene family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. Most of the type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains and are clustered in a region of chromosome 17q12-q21. This keratin has been coexpressed with keratin 14 in a number of epithelial tissues, including esophagus, tongue, and hair follicles. Mutations in this gene are associated with type 1 pachyonychia congenita, non-epidermolytic palmoplantar keratoderma and unilateral palmoplantar verrucous nevus. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).